COMMUNIQUÉS West-GlobeNewswire
-
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
17/03/2026 -
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
17/03/2026 -
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
17/03/2026 -
Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026
17/03/2026 -
Former Peloton and Equinox Design Leader Cecilia Farooqi Joins Noom as Head of Product Design
17/03/2026 -
Microbot Medical® to Participate at the 38th Annual Roth Conference
17/03/2026 -
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
17/03/2026 -
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
17/03/2026 -
Center for Radiology Education Launches Nationwide Initiative to Provide Medical Imaging Scholarships at John Patrick University
17/03/2026 -
Axe Compute Appoints Two Technology and Telecom Luminaries to Board of Directors as Company Accelerates AI Infrastructure Strategy
17/03/2026 -
CoRegen, Inc. Publishes Promising New Data Highlighting SRC-3 Engineered Regulatory T Cells as New Immunotherapy Platform
17/03/2026 -
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
17/03/2026 -
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
17/03/2026 -
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
17/03/2026 -
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
17/03/2026 -
Elicio Therapeutics Reports Inducement Grants
17/03/2026 -
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
17/03/2026 -
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
17/03/2026 -
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
17/03/2026
Pages